Obesity due to excess calories
Conditions
Interventions
This is a randomized, double-blind, placebo-controlled clinical study lasting 90 days, involving 60 participants with a body mass index equal to or greater than 30.0 kilograms per square meter, aged b
a Peptide 19 5 milligram group with 20 individuals who will receive capsules containing 5 milligrams of Peptide 19 plus microcrystalline cellulose excipient and capsule material
and a Peptide 19 10 milligram group with 20 individuals who will receive capsules containing 10 milligrams of Peptide 19 plus microcrystalline cellulose excipient and capsule material. Randomization w
Sponsors
Fundação do abc
Faculdade de Medicina do ABC - Centro Universitário Saúde ABC
Eligibility
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Body mass index greater than or equal to 30.0 kilograms per square meter; age between 18 and 60 years; both sexes; glucose level at a maximum of 125 milligrams per deciliter
Exclusion criteria
Exclusion criteria: Patients with neoplasms; recent infections; chronic liver disease; diagnosed depression under treatment; chronic kidney disease; previous bariatric surgery; lung diseases including chronic obstructive pulmonary disease; recent cardiac event within the last six months; rheumatological diseases and other autoimmune diseases; excessive alcohol consumption; dementia; obesity associated with genetic syndromes; decompensated hypothyroidism; menopausal women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expected to observe the efficacy of white adipose tissue activator peptide cyclophilin A (WATACAP) in reducing body weight and decreasing body fat percentage by body composition, verified through anthropometric assessments and dual-energy X-ray absorptiometry (DEXA), at the end of the 90-day intervention | — |
Secondary
| Measure | Time frame |
|---|---|
| An improvement in the behavior of the inflammatory markers Interleukin 6 (IL6), Tumor Necrosis Factor alpha (TNF alpha), and high-sensitivity C-reactive protein (hs-CRP), verified through laboratory tests, is expected to be observed over the 90 days of the intervention | — |
Countries
Brazil
Contacts
Public ContactDavi Vantini
Centro Universitário FMABC
Outcome results
None listed